New biologics and small molecules in inflammatory bowel disease: an update
Inflammatory bowel disease (IBD) is a spectrum of immune-mediated inflammatory disorders with a complex multifactorial pathogenesis, where different pathways may predominate in different individuals. This complexity will most likely require a panoply of drugs targeting different pathways if one want...
Main Authors: | João Sabino, Bram Verstockt, Séverine Vermeire, Marc Ferrante |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2019-05-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/1756284819853208 |
Similar Items
-
Inflammatory Bowel Disease (IBD)—A Textbook Case for Multi-Centric Banking of Human Biological Materials
by: Isabelle Cleynen, et al.
Published: (2019-10-01) -
Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises
by: Dahham Alsoud, et al.
Published: (2022-01-01) -
Patient preferences for inflammatory bowel disease treatments: protocol development of a global preference survey using a discrete choice experiment
by: Elise Schoefs, et al.
Published: (2024-08-01) -
Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium
by: Brecht Creyns, et al.
Published: (2020-08-01) -
Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
by: Séverine Vermeire, et al.
Published: (2023-08-01)